Heart failure & cardiomyopathiesCohort study

Incremental prognostic value of cardiac magnetic resonance beyond biomarker staging in transthyretin cardiac amyloidosis

Eur Heart J Cardiovasc ImagingPublished

  • retrospectively analyzed a multicentre cohort
  • internal validation via bootstrapping
  • decision curve analysis

Authors' conclusion

CMR-derived ECV and LAVi were associated with incremental prognostic value in ATTR-CA beyond biomarker staging and may inform clinical risk stratification.

Study context

Population
ATTR-CA patients who underwent cardiac magnetic resonance (CMR) between 2007 and 2023ATTR-CA patients who underwent CMR
Participants
266 patients
Exposure
CMR parameters incorporated into National Amyloidosis Centre (NAC) staging vs baseline model using NAC stage

Main finding

As reported in the abstract

Death · median follow-up of 20 months (IQR 8-35)

Patients who died

85 patients (32%)

Observational data: associations, not effects.

Further findings

Mortality, ECV ≥ 59% (after NAC adjustment)

ComparisonHR (95% CI)P value
ECV ≥ 59% · independently associated with mortality after NAC adjustment2.45 (1.2–5.2)P = 0.020

Mortality, LAVi ≥ 54 mL/m² (after NAC adjustment)

ComparisonHR (95% CI)P value
LAVi ≥ 54 mL/m² · independently associated with mortality after NAC adjustment2.00 (1.1–3.7)P = 0.026

Prognostic accuracy

ECV and LAVi improved prognostic accuracy across all biomarker stages

Decision curve analysis: identification of high-risk patients for advanced heart failure (HF) or emerging disease-modifying therapies

additional high-risk patients identified per 1000 with CMR alongside NAC staging
28

Original publication

Incremental prognostic value of cardiac magnetic resonance beyond biomarker staging in transthyretin cardiac amyloidosis. Eur Heart J Cardiovasc Imaging. Published 1 July 2026. doi:10.1093/ehjci/jeag170

Summarised from the published abstract; every number is checked against it